FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2542-2550 December 14, 2006 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.

Methods Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non–small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival.

Results The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.

Conclusions The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non–small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060 [ClinicalTrials.gov] .)

Source Information

From Vanderbilt University, Nashville (A.S., D.H.J.); the Dana–Farber Cancer Institute, Boston (R.G.); the Ellis Fischel Cancer Center, University of Missouri, Columbia (M.C.P.); Johns Hopkins University, Baltimore (J.B.); the University of Wisconsin, Madison (J.H.S.); University Hospitals of Cleveland, Cleveland (A.D.); and Mount Sinai Hospital, Miami (R.L.).

Address reprint requests to Dr. Sandler at the Vanderbilt–Ingram Cancer Center, 2220 Pierce Ave., Nashville, TN 37232, or at alan.sandler{at}vanderbilt.edu.

Full Text of this Article

This article has been cited by other articles:

• Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q.M., Serkova, N. J., Meropol, N. J., Lewis, N. L., Chiorean, E. G., Fox, F., Youssoufian, H., Rowinsky, E. K., Eckhardt, S. G. (2010). Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. JCO 28: 780-787 [Abstract] [Full Text]  
• Simon, G. R. (2010). Treatment of Older Patients With Non-Small-Cell Lung Cancer: Walking the Therapeutic Tightrope. JCO 28: 523-526 [Full Text]  
• Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., Fassnacht, M. (2010). Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 162: 349-356 [Abstract] [Full Text]  
• Mitsudomi, T. (2010). Advances in Target Therapy for Lung Cancer. Jpn J Clin Oncol 40: 101-106 [Abstract] [Full Text]  
• Perez, E. A., Hillman, D. W., Dentchev, T., Le-Lindqwister, N. A., Geeraerts, L. H., Fitch, T. R., Liu, H., Graham, D. L., Kahanic, S. P., Gross, H. M., Patel, T. A., Palmieri, F. M., Dueck, A. C. (2010). North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 21: 269-274 [Abstract] [Full Text]  
• Kreisl, T. N., Kotliarova, S., Butman, J. A., Albert, P. S., Kim, L., Musib, L., Thornton, D., Fine, H. A. (2010). A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncology 12: 181-189 [Abstract] [Full Text]  
• Keefe, S. M., Cohen, M. A., Brose, M. S. (2010). Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications. Clin. Cancer Res. 16: 778-783 [Abstract] [Full Text]  
• Baty, F., Facompre, M., Kaiser, S., Schumacher, M., Pless, M., Bubendorf, L., Savic, S., Marrer, E., Budach, W., Buess, M., Kehren, J., Tamm, M., Brutsche, M. H. (2010). Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non-Small Cell Lung Cancer. Am. J. Respir. Crit. Care Med. 181: 181-188 [Abstract] [Full Text]  
• Tsujino, K., Shiraishi, J., Tsuji, T., Kurata, T., Kawaguchi, T., Kubo, A., Takada, M. (2010). Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?. Ann Oncol 0: mdp588v1-mdp588 [Abstract] [Full Text]  
• Barlesi, F., Balleyguier, C., Besse, B., Bonodeau, F., Brenac, F., Corneloup, O., Dansin, E., Ferretti, G., Gaubert, J. Y., Gervais, R., Lacombe, C., Loundou, A., Moro-Sibilot, D., Planchard, D., Scherpereel, A., Menu, Y. (2010). Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol 0: mdp590v1-mdp590 [Abstract] [Full Text]  
• Hanrahan, E. O., Lin, H. Y., Kim, E. S., Yan, S., Du, D. Z., McKee, K. S., Tran, H. T., Lee, J. J., Ryan, A. J., Langmuir, P., Johnson, B. E., Heymach, J. V. (2010). Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer. JCO 28: 193-201 [Abstract] [Full Text]  
• Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L., Buzenet, G., Koehler, E., Sosman, J. A., Schwartz, L. H., Gultekin, D. H., Koutcher, J. A., Donnelly, E. F., Andal, R., Dancy, I., Spriggs, D. R., Tew, W. P. (2010). Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors. JCO 28: 207-214 [Abstract] [Full Text]  
• Duda, D. G., Ancukiewicz, M., Jain, R. K. (2010). Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?. JCO 28: 183-185 [Full Text]  
• Dowlati, A. (2010). Hunting and Trapping the Vascular Endothelial Growth Factor. JCO 28: 185-187 [Full Text]  
• Azzoli, C. G., Giaccone, G., Temin, S. (2010). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 6: 39-43 [Full Text]  
• Demedts, I. K., Vermaelen, K. Y., van Meerbeeck, J. P. (2010). Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 35: 202-215 [Abstract] [Full Text]  
• Loges, S., Schmidt, T., Carmeliet, P. (2010). Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates. Genes & Cancer 1: 12-25 [Abstract] [Full Text]  
• Korpanty, G., Smyth, E., Sullivan, L. A, Brekken, R. A, Carney, D. N (2010). Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med 235: 3-9 [Abstract] [Full Text]  
• Spigel, D. R., Hainsworth, J. D., Yardley, D. A., Raefsky, E., Patton, J., Peacock, N., Farley, C., Burris, H. A. III, Greco, F. A. (2010). Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab. JCO 28: 43-48 [Abstract] [Full Text]  
• Goss, G. D., Arnold, A., Shepherd, F. A., Dediu, M., Ciuleanu, T.-E., Fenton, D., Zukin, M., Walde, D., Laberge, F., Vincent, M. D., Ellis, P. M., Laurie, S. A., Ding, K., Frymire, E., Gauthier, I., Leighl, N. B., Ho, C., Noble, J., Lee, C. W., Seymour, L. (2010). Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. JCO 28: 49-55 [Abstract] [Full Text]  
• Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., Belani, C. P. (2010). Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer. JCO 28: 56-62 [Abstract] [Full Text]  
• Agarwala, A. K., Hanna, N. H. (2010). Review: Advanced non-small cell lung cancer: the role of maintenance therapy. Therapeutic Advances in Medical Oncology 2: 17-23 [Abstract]  
• Tew, W. P., Gordon, M., Murren, J., Dupont, J., Pezzulli, S., Aghajanian, C., Sabbatini, P., Mendelson, D., Schwartz, L., Gettinger, S., Psyrri, A., Cedarbaum, J. M., Spriggs, D. R. (2010). Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors. Clin. Cancer Res. 16: 358-366 [Abstract] [Full Text]  
• Besse, B., Lasserre, S. F., Compton, P., Huang, J., Augustus, S., Rohr, U.-P. (2010). Bevacizumab Safety in Patients with Central Nervous System Metastases. Clin. Cancer Res. 16: 269-278 [Abstract] [Full Text]  
• Blumenschein, G. R. Jr., Reckamp, K., Stephenson, G. J., O'Rourke, T., Gladish, G., McGreivy, J., Sun, Y.-N., Ye, Y., Parson, M., Sandler, A. (2010). Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer. Clin. Cancer Res. 16: 279-290 [Abstract] [Full Text]  
• Neal, J. W. (2010). Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer. The Oncologist 15: 3-5 [Full Text]  
• Sheth, S. (2010). Current and emerging therapies for patients with advanced non-small-cell lung cancer. Am J Health Syst Pharm 67: S9-S14 [Abstract] [Full Text]  
• Azzoli, C. G., Baker, S. Jr, Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., Giaccone, G. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. JCO 27: 6251-6266 [Abstract] [Full Text]  
• Ellis, L. M., Hicklin, D. J. (2009). Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin. Cancer Res. 15: 7471-7478 [Abstract] [Full Text]  
• Sobrero, A., Bruzzi, P. (2009). Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval. JCO 27: 5868-5873 [Full Text]  
• Horn, L., Dahlberg, S. E., Sandler, A. B., Dowlati, A., Moore, D. F., Murren, J. R., Schiller, J. H. (2009). Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501. JCO 27: 6006-6011 [Abstract] [Full Text]  
• Sikorski, R., Yao, B. (2009). Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Sci Transl Med 1: 10ps11-10ps11 [Full Text]  
• MINNITI, G., MUNI, R., LANZETTA, G., MARCHETTI, P., ENRICI, R. M. (2009). Chemotherapy for Glioblastoma: Current Treatment and Future Perspectives for Cytotoxic and Targeted Agents. Anticancer Res 29: 5171-5184 [Abstract] [Full Text]  
• Sundaram, S., Trivedi, R., Durairaj, C., Ramesh, R., Ambati, B. K., Kompella, U. B. (2009). Targeted Drug and Gene Delivery Systems for Lung Cancer Therapy. Clin. Cancer Res. 15: 7299-7308 [Abstract] [Full Text]  
• Kobold, S., Hegewisch-Becker, S., Oechsle, K., Jordan, K., Bokemeyer, C., Atanackovic, D. (2009). Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?. The Oncologist 14: 1242-1251 [Abstract] [Full Text]  
• Hainsworth, J. D., Spigel, D. R., Thompson, D. S., Murphy, P. B., Lane, C. M., Waterhouse, D. M., Naot, Y., Greco, F. A. (2009). Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site. The Oncologist 14: 1189-1197 [Abstract] [Full Text]  
• Tabernero, J., Macarulla, T. (2009). Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development. JCO 27: 5487-5491 [Full Text]  
• Dorff, T. B., Goldkorn, A., Quinn, D. I. (2009). Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology 1: 183-205 [Abstract]  
• Socinski, M. A., Langer, C. J., Huang, J. E., Kolb, M. M., Compton, P., Wang, L., Akerley, W. (2009). Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases. JCO 27: 5255-5261 [Abstract] [Full Text]  
• Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., Spiro, S., Gower, N., Jitlal, M., Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 5248-5254 [Abstract] [Full Text]  
• O'Connor, J. P.B., Carano, R. A.D., Clamp, A. R., Ross, J., Ho, C. C.K., Jackson, A., Parker, G. J.M., Rose, C. J., Peale, F. V., Friesenhahn, M., Mitchell, C. L., Watson, Y., Roberts, C., Hope, L., Cheung, S., Reslan, H. B., Go, M. A. T., Pacheco, G. J., Wu, X., Cao, T. C., Ross, S., Buonaccorsi, G. A., Davies, K., Hasan, J., Thornton, P., del Puerto, O., Ferrara, N., van Bruggen, N., Jayson, G. C. (2009). Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging. Clin. Cancer Res. 15: 6674-6682 [Abstract] [Full Text]  
• Steeghs, N., Rabelink, T. J., op 't Roodt, J., Batman, E., Cluitmans, F. H. M., Weijl, N. I., de Koning, E., Gelderblom, H. (2009). Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 0: mdp417v1-mdp417 [Abstract] [Full Text]  
• Sorrentino, C., Di Carlo, E. (2009). Expression of IL-32 in Human Lung Cancer Is Related to the Histotype and Metastatic Phenotype. Am. J. Respir. Crit. Care Med. 180: 769-779 [Abstract] [Full Text]  
• Sakakibara, T., Inoue, A., Sugawara, S., Maemondo, M., Ishida, T., Usui, K., Abe, T., Kanbe, M., Watanabe, H., Saijo, Y., Nukiwa, T. (2009). Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 0: mdp401v1-mdp401 [Abstract] [Full Text]  
• West, H., Harpole, D., Travis, W. (2009). Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer. Chest 136: 1112-1118 [Abstract] [Full Text]  
• Maitland, M. L., Kasza, K. E., Karrison, T., Moshier, K., Sit, L., Black, H. R., Undevia, S. D., Stadler, W. M., Elliott, W. J., Ratain, M. J. (2009). Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment. Clin. Cancer Res. 15: 6250-6257 [Abstract] [Full Text]  
• Rini, B. I., Garcia, J. A., Cooney, M. M., Elson, P., Tyler, A., Beatty, K., Bokar, J., Mekhail, T., Bukowski, R.M., Budd, G. T., Triozzi, P., Borden, E., Ivy, P., Chen, H. X., Dowlati, A., Dreicer, R. (2009). A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. Clin. Cancer Res. 15: 6277-6283 [Abstract] [Full Text]  
• Wilcox, R. A., Wada, D. A., Ziesmer, S. C., Elsawa, S. F., Comfere, N. I., Dietz, A. B., Novak, A. J., Witzig, T. E., Feldman, A. L., Pittelkow, M. R., Ansell, S. M. (2009). Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114: 2936-2944 [Abstract] [Full Text]  
• Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kuta, M., van Klaveren, R. J., Chaudhary, S., Gunther, A., Shamsili, S. (2009). Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer. JCO 27: 4481-4486 [Abstract] [Full Text]  
• Cappuzzo, F., Tallini, G., Finocchiaro, G., Wilson, R. S., Ligorio, C., Giordano, L., Toschi, L., Incarbone, M., Cavina, R., Terracciano, L., Roncalli, M., Alloisio, M., Varella-Garcia, M., Franklin, W. A., Santoro, A. (2009). Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 0: mdp357v1-mdp357 [Abstract] [Full Text]  
• Rudin, C. M., Avila-Tang, E., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W., Schwartz, A. G., Vahakangas, K. H., Samet, J. M. (2009). Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clin. Cancer Res. 15: 5646-5661 [Abstract] [Full Text]  
• Blumenschein, G. R. Jr, Gatzemeier, U., Fossella, F., Stewart, D. J., Cupit, L., Cihon, F., O'Leary, J., Reck, M. (2009). Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. JCO 27: 4274-4280 [Abstract] [Full Text]  
• Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., Settleman, J., Kobayashi, S., Mark, E. J., Rodig, S. J., Chirieac, L. R., Kwak, E. L., Lynch, T. J., Iafrate, A. J. (2009). Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. JCO 27: 4247-4253 [Abstract] [Full Text]  
• Horn, L., Pao, W. (2009). EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer. JCO 27: 4232-4235 [Full Text]  
• Lind, J. S.W., Smit, E. F. (2009). Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 95-107 [Abstract]  
• Bepler, G. (2009). Are We Coming Full Circle for Lung Cancer Screening a Second Time?. Am. J. Respir. Crit. Care Med. 180: 384-385 [Full Text]  
• Okita, N. T., Yamada, Y., Takahari, D., Hirashima, Y., Matsubara, J., Kato, K., Hamaguchi, T., Shirao, K., Shimada, Y., Taniguchi, H., Shimoda, T. (2009). Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer. Jpn J Clin Oncol 39: 595-600 [Abstract] [Full Text]  
• Wozniak, A. J., Gadgeel, S. M. (2009). Review: Adjuvant therapy for resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 109-118 [Abstract]  
• Crane, C. H., Winter, K., Regine, W. F., Safran, H., Rich, T. A., Curran, W., Wolff, R. A., Willett, C. G. (2009). Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411. JCO 27: 4096-4102 [Abstract] [Full Text]  
• Eskens, F. A.L.M., Steeghs, N., Verweij, J., Bloem, J. L., Christensen, O., van Doorn, L., Ouwerkerk, J., de Jonge, M. J.A., Nortier, J. W.R., Kraetzschmar, J., Rajagopalan, P., Gelderblom, H. (2009). Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor {beta}, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors. JCO 27: 4169-4176 [Abstract] [Full Text]  
• Chien, A. J., Illi, J. A., Ko, A. H., Korn, W. M., Fong, L., Chen, L.-m., Kashani-Sabet, M., Ryan, C. J., Rosenberg, J. E., Dubey, S., Small, E. J., Jahan, T. M., Hylton, N. M., Yeh, B. M., Huang, Y., Koch, K. M., Moasser, M. M. (2009). A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies. Clin. Cancer Res. 15: 5569-5575 [Abstract] [Full Text]  
• Pao, W., Kris, M. G., Iafrate, A. J., Ladanyi, M., Janne, P. A., Wistuba, I. I., Miake-Lye, R., Herbst, R. S., Carbone, D. P., Johnson, B. E., Lynch, T. J. (2009). Integration of Molecular Profiling into the Lung Cancer Clinic. Clin. Cancer Res. 15: 5317-5322 [Abstract] [Full Text]  
• Pallis, A. G., Gridelli, C., van Meerbeeck, J. P., Greillier, L., Wedding, U., Lacombe, D., Welch, J., Belani, C. P., Aapro, M. (2009). EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 0: mdp360v1-mdp360 [Abstract] [Full Text]  
• Takano, A., Ishikawa, N., Nishino, R., Masuda, K., Yasui, W., Inai, K., Nishimura, H., Ito, H., Nakayama, H., Miyagi, Y., Tsuchiya, E., Kohno, N., Nakamura, Y., Daigo, Y. (2009). Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer. Cancer Res. 69: 6694-6703 [Abstract] [Full Text]  
• Horn, L., Sandler, A. (2009). Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 5040-5048 [Abstract] [Full Text]  
• Schiller, J. H., Larson, T., Ou, S.-H. I., Limentani, S., Sandler, A., Vokes, E., Kim, S., Liau, K., Bycott, P., Olszanski, A. J., von Pawel, J. (2009). Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study. JCO 27: 3836-3841 [Abstract] [Full Text]  
• Fojo, T., Grady, C. (2009). How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI J Natl Cancer Inst 101: 1044-1048 [Abstract] [Full Text]  
• Patel, J. D., Hensing, T. A., Rademaker, A., Hart, E. M., Blum, M. G., Milton, D. T., Bonomi, P. D. (2009). Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer. JCO 27: 3284-3289 [Abstract] [Full Text]  
• Socinski, M. A. (2009). Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?. JCO 27: 3268-3270 [Full Text]  
• Schettino, C., Bareschino, M. A., Rossi, A., Maione, P., Castaldo, V., Mazzeo, N., Sacco, P. C., Ferrara, M. L., Palazzolo, G., Ciardiello, F., Gridelli, C. (2009). Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 5-13 [Abstract]  
• Larkin, J. M.G., Kipps, E. L.S., Powell, C. J., Swanton, C. (2009). Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology 1: 15-27 [Abstract]  
• SHINGYOJI, M., ANDO, S., NISHIMURA, H., NAKAJIMA, T., ISHIKAWA, A., ITAKURA, M., IIZASA, T., KIMURA, H. (2009). VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel. Anticancer Res 29: 2635-2639 [Abstract] [Full Text]  
• Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., Anver, M. R., Shoemaker, R. H., Melillo, G. (2009). Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Molecular Cancer Therapeutics 8: 1867-1877 [Abstract] [Full Text]  
• Banerjee, S., Gore, M. (2009). The Future of Targeted Therapies in Ovarian Cancer. The Oncologist 14: 706-716 [Abstract] [Full Text]  
• Ichihara, E., Ohashi, K., Takigawa, N., Osawa, M., Ogino, A., Tanimoto, M., Kiura, K. (2009). Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo. Cancer Res. 69: 5091-5098 [Abstract] [Full Text]  
• Shord, S. S., Bressler, L. R., Tierney, L. A., Cuellar, S., George, A. (2009). Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 66: 999-1013 [Abstract] [Full Text]  
• Rossi, G., Pelosi, G., Graziano, P., Barbareschi, M., Papotti, M. (2009). Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. INT J SURG PATHOL 17: 206-218 [Abstract]  
• RICE, S. D., BUSH, J. E., BROWER, S. L. (2009). Assessment of Erlotinib in Chemoresponse Assay. Anticancer Res 29: 1993-1997 [Abstract] [Full Text]  
• Courtwright, A., Siamakpour-Reihani, S., Arbiser, J. L., Banet, N., Hilliard, E., Fried, L., Livasy, C., Ketelsen, D., Nepal, D. B., Perou, C. M., Patterson, C., Klauber-DeMore, N. (2009). Secreted Frizzle-Related Protein 2 Stimulates Angiogenesis via a Calcineurin/NFAT Signaling Pathway. Cancer Res. 69: 4621-4628 [Abstract] [Full Text]  
• Chi, A. S., Sorensen, A. G., Jain, R. K., Batchelor, T. T. (2009). Angiogenesis as a Therapeutic Target in Malignant Gliomas. The Oncologist 14: 621-636 [Abstract] [Full Text]  
• Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capo, A., Germonpre, P., Eberhardt, W. E.E., Stockman, P. K., Kennedy, S. J., Ranson, M. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. JCO 27: 2523-2529 [Abstract] [Full Text]  
• Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G. Jr, Johnson, F. M., Green, S., Gualberto, A. (2009). Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. JCO 27: 2516-2522 [Abstract] [Full Text]  
• Hanrahan, E. O., Ryan, A. J., Mann, H., Kennedy, S. J., Langmuir, P., Natale, R. B., Herbst, R. S., Johnson, B. E., Heymach, J. V. (2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer. Clin. Cancer Res. 15: 3600-3609 [Abstract] [Full Text]  
• Naumov, G. N., Nilsson, M. B., Cascone, T., Briggs, A., Straume, O., Akslen, L. A., Lifshits, E., Byers, L. A., Xu, L., Wu, H.-k., Janne, P., Kobayashi, S., Halmos, B., Tenen, D., Tang, X. M., Engelman, J., Yeap, B., Folkman, J., Johnson, B. E., Heymach, J. V. (2009). Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance. Clin. Cancer Res. 15: 3484-3494 [Abstract] [Full Text]  
• Goss, G., Ferry, D., Wierzbicki, R., Laurie, S. A., Thompson, J., Biesma, B., Hirsch, F. R., Varella-Garcia, M., Duffield, E., Ataman, O. U., Zarenda, M., Armour, A. A. (2009). Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. JCO 27: 2253-2260 [Abstract] [Full Text]  
• Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., Spano, J. P. (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815 [Abstract] [Full Text]  
• McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R., Tam, A., Lee, D. Y., Lucien, L., Brannigan, B. W., Ulkus, L. E., Ma, X.-J., Erlander, M. G., Haber, D. A., Sharma, S. V., Settleman, J. (2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-{alpha} Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Res. 69: 3937-3946 [Abstract] [Full Text]  
• HIROSE, T., SUGIYAMA, T., KUSUMOTO, S., SHIRAI, T., NAKASHIMA, M., YAMAOKA, T., OKUDA, K., OGURA, K., OHNISHI, T., OHMORI, T., ADACHI, M. (2009). Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer. Anticancer Res 29: 1733-1738 [Abstract] [Full Text]  
• Ren, H., Chu, Z., Mao, L. (2009). Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Molecular Cancer Therapeutics 8: 1106-1112 [Abstract] [Full Text]  
• Savci-Heijink, C. D., Kosari, F., Aubry, M.-C., Caron, B. L., Sun, Z., Yang, P., Vasmatzis, G. (2009). The Role of Desmoglein-3 in the Diagnosis of Squamous Cell Carcinoma of the Lung. Am. J. Pathol. 174: 1629-1637 [Abstract] [Full Text]  
• Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., Vinante, O., Pronzato, P., Pappagallo, G. (2009). Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. The Oncologist 14: 497-510 [Abstract] [Full Text]  
• D'Addario, G., Felip, E., On behalf of the ESMO Guidelines Working Group, (2009). Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv68-iv70 [Full Text]  
• Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., Gefen, N., Izraeli, S., Rechavi, G., Pass, H., Nonaka, D., Li, J., Spector, Y., Rosenfeld, N., Chajut, A., Cohen, D., Aharonov, R., Mansukhani, M. (2009). Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non-Small-Cell Lung Carcinoma. JCO 27: 2030-2037 [Abstract] [Full Text]  
• Chhatwani, L., Cabebe, E., Wakelee, H. A. (2009). Adjuvant Treatment of Resected Lung Cancer. Proc Am Thorac Soc 6: 194-200 [Abstract] [Full Text]  
• Horn, L., Sandler, A. B. (2009). Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 206-217 [Abstract] [Full Text]